Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6192)
  2. Meeting Abstract (6164)
  3. Review (400)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (159)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11088)
  2. Hematologic Malignancies, Division of (10639)
  3. GSK Faculty (5447)
  4. Adult Leukemia (3722)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (944)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (310)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (267)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1668)
  3. Nature Publishing Group (1117)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13546)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience
    Meeting Abstract

    O'connor, O.; Wright, J.; Moskowitz, C.; Straus, D.; Portlock, C.; Hamlin, P.; Neylon, E.; Evans, A.; Winter, J.; Gordon, L.; more...
    Annals of Oncology (2005)

    Fulltext@MSK | Save
  • Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease
    Meeting Abstract

    O'connor, O.; Straus, D.; Moskowitz, C.; Hamlin, P.; Portlock, C.; Gerecitano, J.; Neylon, E.; Colevas, D.; Zelenetz, A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity
    Meeting Abstract

    O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma
    Meeting Abstract

    Molina, A. M.; Advani, R.; Reddy, S.; Hoppe, R.; Friedberg, J. W.; Sadan, S.; Myskowski, P.; Kim, Y. H.; Horwitz, S. M.
    Blood (2005)

    Fulltext@MSK | Save
  • Generation of specific human CD8+T cell responses to the myeloproliferative disorder associated V617F mutated JAK2 kinase by use of analog peptide vaccine candidates
    Meeting Abstract

    May, R. J.; Korontsvit, T.; Zakhaleva, V.; Gomez, M.; Dao, T.; Scheinberg, D. A.
    Blood (2005)

    Fulltext@MSK | Save
  • Signaling profiles of T cells during allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Lu, S. X.; Hubbard, V. M.; Chow, M. Y.; Kim, T. D.; Suh, D. Y.; Kochman, A.; Zakrzewski, J.; Cabrera-Perez, J.; Alpdogan, O.; van den Brink, M. R. M.
    Blood (2005)

    Fulltext@MSK | Save
  • Prospective validation of the FLIPI: Baseline distribution and correlates in newly diagnosed follicular lymphoma (FL) patients from the US: First report of The National LymphoCare Study
    Meeting Abstract

    Link, B. K.; Cerhan, J. R.; Dillon, H.; Farber, C. M.; Feliciano, S.; Friedberg, J. W.; Hainsworth, J.; Steis, R.; Vose, J. M.; Zelenetz, A. D.
    Blood (2005)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
    Meeting Abstract

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Potential impact of pathologic review on therapy in non-Hodgkin's lymphoma (NHL): Analysis from the national comprehensive cancer network (NCCN) NHL outcomes project
    Meeting Abstract

    LaCasce, A.; Niland, J.; Kho, M. E.; TerVeer, A.; Friedberg, J. W.; Rodriguez, M. A.; Czuczman, M. S.; Millenson, M.; Zelenetz, A. D.; Nademanee, A. P.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Radiation therapy for Ewing's sarcoma
    Meeting Abstract

    La, T. H.; Meyers, P. A.; Wexler, L. H.; Healey, J. H.; La Quaglia, M. P.; Boland, P. J.; Wolden, S. L.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save